What Are the Second-Line Treatments for Acromegaly?

If your first medication for acromegaly hasn’t fully lowered your IGF-1 (Insulin-like Growth Factor-1, the hormone that causes most acromegaly symptoms) into the normal range, it is completely normal and expected that your doctor will adjust your treatment ^[1]. Acromegaly management is often a process of trial and error. The first-line medical treatments—usually first-generation somatostatin receptor ligands (SRLs) like octreotide or lanreotide—work well for many, but not all patients.

If these do not fully control your disease, your endocrinologist has several powerful “second-line” backup plans. Finding the right medical “cocktail” to control your hormones is standard practice. Failing your first medication simply helps your doctor figure out what will work best for your specific biology ^[1][2]. (Note: While this page focuses on medication, repeat surgery or radiation therapy are also sometimes considered at this stage to help control the disease).

Adding a Medication (Combination Therapy)

Instead of stopping your first medication, your doctor might choose to add a second drug to your regimen. Combining different classes of medications is currently considered the most effective way to achieve normal hormone levels in resistant cases ^[3][2].

• Adding Pegvisomant: Pegvisomant is a highly effective daily injection that works differently than SRLs. Instead of targeting the pituitary tumor, it blocks the effects of growth hormone throughout your body, particularly in the liver, preventing it from making excess IGF-1 ^[3]. Adding pegvisomant to an SRL is highly successful, with some studies showing it normalizes IGF-1 in a vast majority of patients (up to 96% in some combination regimens) ^[3][2]. Because it is a daily injection, there is a risk of localized skin and fat changes at the injection site, so rotating where you inject is important ^[4]. Additionally, pegvisomant can occasionally cause a temporary increase in liver enzymes, so your doctor will monitor your liver blood tests regularly ^[4][2].
• Adding Cabergoline: Cabergoline is an oral pill known as a dopamine agonist. It is usually most helpful as an add-on therapy for patients whose IGF-1 levels are only slightly elevated above normal (less than 1.5 times the upper limit) ^[5][6]. Because it is a pill rather than an injection, it is often favored by patients looking to avoid extra shots, provided their levels are low enough for it to be effective. Common side effects can include nausea, dizziness, or upset stomach when you first start taking it ^[7].

Switching to a New Medication

Depending on your tumor’s characteristics, your doctor might decide to stop your first medication completely and switch you to a different class of drug ^[1][8].

• Switching to Pasireotide (Signifor LAR): Pasireotide is a “next-generation” SRL given as a once-a-month injection, typically by a healthcare professional. It binds to a broader set of receptors on your pituitary tumor compared to first-generation drugs like octreotide ^[8]. It can effectively achieve disease control for about 15% to 20% of patients who saw no benefit from their first medication ^[2]. However, pasireotide carries a high risk of causing or worsening high blood sugar (hyperglycemia) and diabetes ^[9][10]. If you are prescribed pasireotide, your care team will proactively monitor your blood sugar and may need to prescribe antidiabetic medications ^[11][12].

Emerging Oral Options

Historically, most acromegaly treatments have been injections. However, new oral alternatives, such as daily oral octreotide and newer oral medications like paltusotine, are emerging ^[13][14]. While they are typically prescribed to maintain control once your hormone levels have successfully stabilized on an injectable therapy, they represent a future opportunity to transition to a more convenient, pill-based routine once the right combination of second-line treatments gets your acromegaly under control.

How Your Doctor Chooses

Deciding which path to take—switching versus adding, or choosing pegvisomant versus pasireotide—is highly personalized ^[15]. Your endocrinologist will consider several factors:

• Your blood sugar history: If you already have pre-diabetes or diabetes, pasireotide might be avoided ^[9].
• Tumor growth: If your tumor is growing, a tumor-targeting drug like pasireotide might be prioritized. If the tumor size is stable but your IGF-1 is high, pegvisomant is a strong option ^[8]. However, because pegvisomant only controls the hormone and not the tumor, patients on this drug will still need routine MRI scans to monitor for any tumor growth.
• How close you are to normal: Mild elevations might just need a cabergoline pill added to your current regimen ^[6].

It typically takes a few weeks to a few months to see if a new second-line medication or combination therapy is working. Remember that navigating second-line treatments is a very standard phase of acromegaly care. It may take some time and adjustments, but with these multiple options, long-term disease control is highly achievable ^[16][17].